Posterolateral Spinal Fusion (PLF) — Lumbar Fusion Surgery, Evidence & Outcomes — Cost, Top Hospitals & Success Rates | MyMedicPlus

Posterolateral spinal fusion (PLF) is a surgical technique in which bone graft is placed in the intertransverse region lateral to the lumbar spine — between the transverse processes and across the facet joints — to stimulate a solid bony bridge across one or more vertebral segments. Unlike interbody fusion techniques (PLIF, TLIF, ALIF) which restore disc height and achieve anterior column support, PLF achieves posterior column fusion without disturbing the disc space, relying on cortical and cancellous contact between the decorticated transverse processes, facets, and adjacent bony surfaces.

Modern instrumented PLF combines bilateral pedicle screw-rod fixation (to provide immediate stabilisation while fusion matures) with bone graft placed in the intertransverse space. This approach achieves fusion rates of 85–95% on CT at 12 months — substantially superior to non-instrumented PLF (60–70%) in which fusion relies entirely on bone graft without internal fixation. Non-instrumented PLF is now rarely performed as the primary procedure.

The procedure typically involves a posterior midline skin incision with subperiosteal dissection of the paraspinal muscles off the laminae and transverse processes, followed by laminectomy or laminotomy for decompression where indicated, pedicle screw placement under fluoroscopic or navigation guidance, decortication of the transverse processes and facet joints, and bone graft application. Operating time ranges from 2 to 5 hours depending on the number of levels fused and whether concurrent decompression is performed.

Two landmark randomised controlled trials have defined the evidence base for PLF. The SPORT trial (Weinstein et al., JAMA 2007) demonstrated superior outcomes in surgical vs non-operative management for degenerative spondylolisthesis at 4 years. The SLIP trial (Ghogawala et al., NEJM 2016) directly compared decompression-plus-fusion to decompression-alone for Grade I degenerative spondylolisthesis, demonstrating significantly better quality-of-life scores and lower reoperation rates in the fusion group at 2 and 4 years, firmly establishing instrumented PLF as the standard of care for this indication.

PLF is indicated across a range of lumbar spinal conditions characterised by instability, deformity, or pain refractory to conservative management:

• Degenerative lumbar spondylolisthesis (Grade I–II): The most common indication; typically at L4/L5; SLIP trial established instrumented PLF as superior to decompression alone; addresses both stenosis (via laminectomy/laminotomy) and instability (via fusion).
• Isthmic (pars defect) spondylolisthesis: Bilateral pars interarticularis fractures most commonly at L5/S1 in younger, more active patients; PLF restores stability and relieves radiculopathy from foraminal stenosis.
• Degenerative disc disease with mechanical back pain: After failure of ≥6 months of structured conservative management including physiotherapy, injections, and lifestyle modification; PLF eliminates painful motion at the affected segment, though outcomes for back pain alone are less predictable than for radiculopathy-predominant disease.
• Spinal stenosis with dynamic instability: When decompressive laminectomy alone would create or exacerbate iatrogenic instability (e.g., grade I spondylolisthesis with dynamic translation >3–4 mm, or facet joint resection exceeding 50%).
• Recurrent disc herniation with instability: Repeat discectomy at the same level carries increasing risk of recurrence and instability; fusion at the recurrent level may be appropriate after 2 or more recurrences.
• Adult degenerative scoliosis: As part of multi-level deformity correction procedures aimed at restoring coronal and sagittal balance; typically combined with interbody fusion for optimal lordosis restoration.
• Pseudarthrosis after prior fusion: Revision PLF when previous fusion has failed radiologically (Bridwell Grade III or IV on CT) and is associated with persistent or recurrent symptoms; requires assessment of underlying cause (infection, metabolic bone disease, smoking status, hardware failure).
• Post-discectomy instability: Progressive back pain and instability following prior laminectomy or discectomy at the same level, particularly in the context of facet joint degeneration.

Appropriate patient selection is critical to outcomes in PLF. Candidates should meet the following criteria:

• Radiological instability confirmed: Dynamic (flexion-extension) radiographs demonstrating ≥3–4 mm translation or ≥10° of angular motion at the affected level, OR MRI-confirmed significant foraminal or central stenosis driving the radiculopathy or neurogenic claudication.
• Failed structured conservative management (minimum 6 months): A minimum 6-month course of structured physiotherapy targeting core stabilisation and lumbar function, combined with analgesic optimisation, NSAIDs, and epidural steroid injections (ESI) where appropriate.
• Significant functional impact: Leg pain (VAS ≥5/10), functional limitation (Oswestry Disability Index ≥40%), or progressive neurological deficit (foot drop, bowel or bladder involvement — the latter requiring urgent referral).
• Adequate bone quality for pedicle screw purchase: CT pedicle morphology assessment; DEXA scan if osteoporosis is suspected (T-score ≤−2.5 requires augmentation strategies: cement-augmented screws, denosumab, teriparatide pre-treatment for 3–6 months).
• Smoking cessation confirmed: Active smoking reduces fusion rates by approximately 2-fold (OR 2.3 for pseudarthrosis vs non-smokers); pre-operative cessation of at least 4–8 weeks is strongly advised; nicotine replacement therapy also impairs fusion and should be converted to oral pharmacotherapy (varenicline, bupropion).
• BMI and cardiovascular fitness: Obesity (BMI >35 kg/m²) increases wound infection risk 3-fold and reduces functional recovery; not an absolute contraindication but warrants pre-operative optimisation and MDT review. Cardiopulmonary fitness assessed for general anaesthesia.
• Psychological assessment: Pre-operative fear-avoidance beliefs, depression, and catastrophisation are strong independent predictors of poor surgical outcomes; psychological optimisation (CBT, pain management programme) should precede elective PLF where significant psychosocial flags are identified.

Instrumented posterolateral fusion (standard technique):

Bilateral pedicle screws are placed after posterior decompression (laminectomy, laminotomy, or foraminotomy as required). Rod connection provides immediate segment stability. The transverse processes and facet joints are decorticated with a high-speed burr to create a bleeding bone surface that promotes graft incorporation. Bone graft is packed into the intertransverse space bilaterally. This is the technique studied in the SPORT and SLIP trials.

Bone graft options — comparative evidence:

• Iliac crest bone graft (ICBG): Considered the gold standard for biological fusion potential. 10–30 cc of corticocancellous graft harvested from the posterior iliac crest through a separate incision or through the same midline wound. Fusion rates 85–95%. Donor site complications occur in 20–30% of patients: persistent chronic pain at the harvest site (most common), sensory disturbance, haematoma, and rarely hernia through the graft window.
• Recombinant human BMP-2 (rhBMP-2, INFUSE, Medtronic): FDA-approved for lumbar PLF in specific formulations. Applied on an absorbable collagen sponge placed in the intertransverse space. Fusion rates equivalent to ICBG in industry-sponsored RCTs. Completely eliminates donor site morbidity. Concerns include: ectopic bone formation when used posteriorly (affecting neural elements), post-operative radiculitis in 5–10%, and theoretical oncogenic risk at supraphysiological doses — which has led to more conservative use since the 2011 Spine Journal independent reassessment.
• Bone graft extenders: Demineralised bone matrix (DBM), synthetic tricalcium phosphate ceramics, and hydroxyapatite scaffolds are used in combination with ICBG to reduce the volume of autograft required while maintaining fusion potential. Standalone ceramic extenders are not equivalent to ICBG in PLF.
• Bone marrow aspirate (BMA): Mesenchymal stem cells aspirated from the posterior iliac crest and combined with extender scaffolds; used when ICBG volume is insufficient; evidence base less robust than ICBG alone.

Non-instrumented PLF: Fusion rates 60–70%; rarely used as the primary approach for spondylolisthesis; may be used as an adjunct to interbody fusion for additional posterior column grafting.

SLIP trial (Ghogawala et al., NEJM 2016): 66 patients with Grade I degenerative spondylolisthesis randomised to laminectomy alone vs laminectomy + instrumented PLF. At 2 years: SF-36 physical function score significantly higher in fusion group (+5.2 points). At 4 years: reoperation rate 14% (fusion) vs 34% (laminectomy alone). This trial reversed prior practice in many centres.

SPORT trial (Weinstein et al., JAMA 2007–2009): 607 patients enrolled; as-treated analysis showed significantly greater improvement in bodily pain and physical function in surgical vs non-operative patients at 4 years, sustained to 8 years in the observational cohort, particularly for patients with spondylolisthesis plus stenosis.

When performed in well-selected patients after failure of appropriate conservative management, instrumented PLF delivers consistent and durable benefits:

• Effective radicular pain relief: 70–85% of patients report significant improvement in leg pain (VAS reduction ≥3 points) by 6 months; outcomes for radiculopathy and neurogenic claudication are generally superior to outcomes for isolated axial back pain.
• Improved walking distance and functional capacity: Mean Oswestry Disability Index (ODI) reduction of 20–30 points at 12 months in RCT populations; patients with pre-operative neurogenic claudication typically recover walking distance within 3–6 months.
• High radiological fusion rates: CT-confirmed solid fusion in 85–95% of instrumented PLF cases at 12 months (Bridwell Grade I or II fusion), providing durable structural stability.
• Prevention of neurological deterioration: Fusion in patients with dynamic instability prevents progressive neurological deficit that may result from untreated spondylolisthesis.
• Durable long-term outcomes: SPORT 8-year observational data and SLIP 4-year RCT data both show maintained superiority of surgical management over non-operative care and decompression-alone.
• Reduced reoperation rates: SLIP trial demonstrated reoperation rate of 14% (fusion) vs 34% (decompression alone) at 4 years — a 59% relative reduction in the need for further surgery.
• Avoidance of donor site morbidity with BMP-2: Rheumatoid BMP-2 eliminates the 20–30% chronic donor site pain associated with ICBG harvest, at the cost of higher per-procedure implant expense.
• Rapid mobilisation with modern instrumentation: Pedicle screw fixation allows same-day or next-day mobilisation with physiotherapy, reducing post-operative deconditioning and hospital length of stay.

PLF is major surgery with a recognised complication profile that must be discussed in full during pre-operative consent:

• Pseudarthrosis (failure of fusion): Occurs in 5–15% of instrumented PLF cases; higher rates with obesity, smoking, osteoporosis, multi-level fusion, and diabetes. Symptomatic pseudarthrosis presents with persistent or worsening back pain; confirmed on thin-slice CT (absence of bridging bone, hardware failure). Requires revision surgery with augmented graft strategy.
• Adjacent segment disease (ASD): Radiological degeneration at levels immediately above or below the fusion occurring in up to 24% at 5 years, with symptomatic ASD requiring further surgery in 2–4% per patient-year. Risk increases with number of fused levels, age at primary surgery, and degree of pre-existing adjacent segment degeneration. The L3/4 segment above an L4–S1 fusion is most commonly affected.
• Surgical site infection (SSI): Superficial wound infection in 1–3%; deep SSI involving the instrumented levels in 0.5–2%; Staphylococcus aureus most common pathogen. Treatment requires prolonged IV antibiotic therapy; deep infection typically requires surgical debridement with or without implant removal. Single-dose IV cefazolin within 60 minutes of incision reduces SSI risk.
• Hardware failure: Pedicle screw fracture or loosening in 5–10% (majority asymptomatic); rod breakage at the pseudarthrosis site. Symptomatic hardware failure requiring revision in 1–3% of cases; more common in osteoporotic bone.
• Neurological injury: New or worsened neurological deficit in under 1% of cases; incidental durotomy (dural tear) in 1–4%, managed with primary repair and fat graft or fibrin sealant; post-operative radiculopathy from retraction or haematoma in 2–5% (usually transient).
• Blood loss and transfusion: Average blood loss 400–800 mL for single-level PLF; higher for multi-level or revision surgery. Intraoperative cell salvage, pre-operative iron optimisation, and IV tranexamic acid (TXA) significantly reduce allogenic transfusion requirements.
• BMP-2 specific complications: Post-operative radiculitis in 5–10% (inflammatory reaction to the collagen sponge carrier); ectopic bone formation in the epidural space or foramen if used posteriorly; concerns regarding malignancy risk at supraphysiological doses in the 2011 independent assessment led to label updates.
• Donor site complications (ICBG): Chronic harvest site pain in 20–30%; sensory loss over the superior gluteal nerve territory; superficial haematoma; very rarely, superior gluteal artery injury or hernia through the bone window.
• Venous thromboembolism (VTE): DVT in 1–3%; PE in 0.1–0.5%; LMWH prophylaxis commenced within 24–48 hours of surgery and continued for 14–28 days.

Immediate post-operative period (Days 0–5):

• Day 1: Mobilisation with physiotherapist to sitting and standing; urinary catheter removal; commence LMWH thromboprophylaxis.
• Days 2–4: Supervised mobilisation with walking frame progressing to walking stick; wound assessment; analgesic step-down (IV to oral); blood tests including CRP and FBC.
• Day 2–4: Hospital discharge in uncomplicated single-level PLF; complex multi-level cases may require 5–7 days.

Weeks 2–6:

• Wound review at 2 weeks; suture or staple removal; neurological assessment.
• Activity restrictions: No lifting over 5 kg; no driving (typically 6 weeks); avoid prolonged sitting; graduated walking programme (aim 20–30 minutes daily by week 4).
• Lumbar brace: Evidence for routine bracing is equivocal; used selectively in patients with osteoporosis or poor compliance.

3 months:

• Clinic review with plain radiographs (AP and lateral); assess for early fusion signs (bridging trabecular bone on lateral view); hardware position confirmation.
• Begin formal physiotherapy programme: trunk strengthening (transversus abdominis activation, multifidus re-education), aerobic conditioning, posture education.

6 months:

• Functional assessment; MRI if new or persistent radiculopathy develops; assessment for return to work including occupational therapy evaluation for physical roles.

12 months:

• CT scan is the gold standard for fusion assessment (Bridwell Classification: Grade I = complete bridging bilateral; Grade II = unilateral bridging; Grade III = graft intact but non-bridging; Grade IV = graft resorbed); functional outcome scores (ODI, VAS back and leg); return to heavy physical labour generally achievable by 12 months.

2 years:

• Final assessment; dynamic flexion-extension films to assess adjacent segment; disc height and facet joint morphology at adjacent levels; MRI only if symptomatic.
• Long-term: Annual review for multi-level fusions; osteoporosis management; bone density DEXA at 5 years.

PLF is a major surgical procedure with costs that vary substantially by country, hospital sector, and complexity:

United States:

• Total hospital and surgical costs for single-level instrumented PLF: $50,000–100,000 USD
• Pedicle screw-rod system (implant cost alone): $3,000–12,000
• rhBMP-2 (INFUSE kit, Medtronic): $4,000–6,000 per kit
• Anaesthesia and facility fees: $15,000–30,000
• Intraoperative neurophysiological monitoring (IONM): $800–2,000 additional
• Navigation or robotic-assisted PLF: $3,000–8,000 additional

United Kingdom (NHS):

• Available on the NHS under spinal surgery tariffs; typical NHS waiting times 12–24 months
• Private single-level instrumented PLF: £15,000–30,000 including implants and inpatient stay

India (medical tourism):

• Instrumented PLF including implants, hospital stay, and anaesthesia: $4,500–9,000 USD at accredited hospitals (Apollo, Fortis, Manipal, Max)
• India is among the most cost-competitive destinations for spinal surgery with internationally trained surgeons and NABH/JCI-accredited facilities

Thailand and Malaysia:

• $6,000–12,000 USD at internationally accredited private hospitals (Bumrungrad, Pantai, Gleneagles)

Key cost drivers:

• Number of levels fused: Each additional level adds approximately $10,000–20,000 in the US
• Revision vs primary surgery: Revision PLF costs 40–60% more due to longer operating time, increased blood loss, and higher implant complexity
• BMP-2 use: $4,000–6,000 per kit
• Complication management: Deep SSI requiring debridement adds $10,000–30,000; reoperation for pseudarthrosis is similarly expensive
• Rehabilitation: Inpatient rehabilitation facility costs $1,000–2,500/day in the US if required post-operatively

Non-surgical alternatives should be exhausted before elective PLF and may provide adequate long-term relief in a significant proportion of patients:

• Structured physiotherapy and rehabilitation: The primary conservative treatment for mechanical low back pain and mild spondylolisthesis. The SPORT non-operative arm showed meaningful improvement in 30–40% of conservatively treated patients at 2 years. A structured programme targeting transversus abdominis, multifidus re-education, and aerobic conditioning — supervised by a spinal physiotherapist — is the cornerstone of non-surgical management.
• Epidural steroid injections (ESI): Effective for acute radiculopathy; benefits typically persist 3–6 months; not a long-term solution for structural instability but valuable as a diagnostic and therapeutic bridge. Interlaminar or transforaminal approaches; 1–3 injections may be trialled before surgical referral.
• Facet joint injections and medial branch blocks (MBB): For facet-mediated pain components; radiofrequency ablation (RFA) of the medial branches provides 6–18 months of sustained pain relief in well-selected patients; may be repeated.
• Transforaminal lumbar interbody fusion (TLIF): For single-level disease with significant disc height loss, foraminal stenosis, or lumbar lordosis deficiency, standalone TLIF or combined TLIF + PLF provides anterior column support and better lordosis restoration than PLF alone; fusion rates comparable at 85–95%.
• Anterior lumbar interbody fusion (ALIF): Retroperitoneal anterior approach; excellent anterior column access; large lordotic cages restore disc height and foraminal height; risks include retrograde ejaculation (0.5–2% in males) from superior hypogastric plexus injury.
• Lumbar total disc replacement (TDR): FDA-approved for single-level L4/5 or L5/S1 degenerative disc disease in the absence of facet joint disease, instability, or osteoporosis; preserves adjacent segment mobility; 5-year RCT data show equivalent outcomes to fusion for back pain-dominant single-level disease; not appropriate for spondylolisthesis requiring stabilisation.
• Spinal cord stimulation (SCS): For patients with failed back surgery syndrome (FBSS) after prior spinal surgery who are not candidates for revision; provides 50–70% pain reduction in well-selected candidates; cost-effective vs repeat revision surgery in FBSS.
• Continued conservative management with watchful waiting: For patients with mild-to-moderate symptoms (ODI <30%) and stable neurology; serial imaging monitoring for progression; most degenerative spondylolisthesis does not progress rapidly and surgery can be deferred safely.